TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES

FLUROTECH LTD. ("TEST.H")
  [formerly FluroTech Ltd. ("TEST")]
  BULLETIN TYPE: Transfer and New Addition to NEX, Symbol Change, Resume Trading
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2 Company

Effective at the opening, Monday, October 30, 2023 , the securities of FluroTech Ltd., (the "Company") will resume trading.  Further to the Exchange Bulletin dated April 17, 2023 , a news release was issued on October 6, 2023 , announcing that the Company will not be proceeding with its proposed transaction.  The transaction contemplated would have constituted a Reverse Takeover as defined under Exchange Policy 5.2.

In accordance with TSX Venture Policy 2.5, the Company has not maintained the requirements for a TSX Venture Tier 2 company.  Therefore, effective at the opening on Monday, October 30, 2023 , the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Calgary to NEX.

As of October 30, 2023 the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies.

The trading symbol for the Company will change from TEST to TEST.H.  There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital.  The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market.

________________________________________

Right Season Investments Corp. ("LITT")
  BULLETIN TYPE:  Consolidation
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2   Company

Pursuant to a resolution passed by the shareholders of the Company on October 20, 2023 , the Company has consolidated its capital on a seventy (70) old for one (1)  new basis.  The name of the Company has not been changed.

Effective at the opening October 30, 2023 , the shares of Right Season Investments Corp. will commence trading on TSX Venture Exchange on a consolidated basis. The Company is classified as a 'Financial Services - Investment Companies and Funds' company.

Post - Consolidation

Capitalization:                          Unlimited   shares with no par value of which

2,262,956   shares are issued and outstanding

Escrow                                     Nil   shares are subject to escrow

Transfer Agent:                        Endeavor Trust Corporation

Trading Symbol:                       LITT                  ( UNCHANGED )

CUSIP Number:                       76658Q206 (NEW)

________________________________________

STALLION URANIUM CORP. ("STUD   ")
  [formerly STALLION DISCOVERIES CORP. ("STUD   ")]
  BULLETIN TYPE:  Name Change
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2   Company

Pursuant to a resolution passed by directors on October 11, 2023 , the Company has changed its name as follows.  There is no consolidation of capital.

Effective at the opening October 30, 2023 , the common shares of  Stallion Uranium Corp. will commence trading on TSX Venture Exchange, and the common shares of Stallion Discoveries Corp. will be delisted.  The Company is classified as a 'Mining' company.

Capitalization:                                     Unlimited  shares with no par value of which

109,381,286  shares are issued and outstanding

Escrow:                                               nil  common shares

Transfer Agent:                                   Endeavor Trust Corporation

Trading Symbol:                                  STUD                   ( UNCHANGED )

CUSIP Number:                                  852919109            ( NEW )

________________________________________

Sucro Limited   ("SUG")
  B   ULLETIN TYPE: New Listing-Shares
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2 Company

The Prospectus of Sucro Limited ("Sucro") dated October 19, 2023 (the "Prospectus") has been filed with and accepted by the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Commissions, effective October 23, 2023 , pursuant to the provisions of the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Acts.

The subordinate voting shares (the "SVS") of the Company will be listed and admitted to trading on TSX Venture Exchange, on the effective dates stated below. Each Proportionate Voting Shares ("PVS") is convertible into one hundred (100) SVS. Only the SVS will be listed on the Exchange.

The gross proceeds to be received by the Company for the Offering Are C$15,004,000 , being 1,364,000 SVS at C$11 per SVS, plus up to an additional 15% if over-allotment option is exercised in full.

Listing Date:                  At the close of business ( 5:01 p.m. EDT ) on Friday, October 27, 2023 .

Commence Date:          The SVS will commence trading on TSX Venture Exchange at the opening on Monday, October 30, 2023 , upon confirmation of closing.

The closing of the public offering is scheduled to occur before the market opening on Monday, October 30, 2023 . A further notice will be issued upon receipt of closing confirmation.

For further information, please refer to the Company's Prospectus dated October 19, 2023 available on SEDAR+ and to the Company's news releases dated October 23, 2023 .

Corporate Jurisdiction: Cayman Islands

Capitalization:

Authorized:       490,000,000 SVS and 1,000,000 PVS

with a par value of US$0.0001 per SVS and US$0.001 per PVS, of which

Issued and Outstanding: 6,528,421 SVS and 167,189 PVS (not listed)

Escrowed Securities:     1,153,244 SVS and 167,189 PVS of which

115,324 SVS and 16,718 PVS are released as at the date of this bulletin

Transfer Agent:             Odyssey Trust Company

Trading Symbol: SUG

CUSIP Number: G8544S107

The Company is classified as a "Sugar Manufacturing" company (NAICS: 311310).

Company Contact:                    Stefano D'Aniello, CFO

Company Address:                   2020 Ponce de Leon Blvd., Suite 1204 Coral Gables, Florida 33134 USA Company Phone Number:             (305) 901-1322

Company Email Address: sdaniello@sucro.us

Company Website: www.sucro.us

________________________________________

THE WELL TOLD COMPANY INC.   ("WLCO.H")
 

LITT:CC
The Conversation (0)
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less
Nutritional Growth Solutions Limited

Binding Commitments Received for A$1.0 Million under Convertible Note Placement

Nutritional Growth Solutions Limited (ASX:NGS) ("NGS" or "the Company"), is pleased to announce that it has received binding commitments for the issue of 1,000,000 convertible notes (Placement CNs), to be issued at $1.00 each (CN Placement).

Keep reading...Show less

Latest Press Releases

Related News

×